Marburg virus disease: a brief updated overview

Ahmed Elhamalawy; Rahaf Elgonaid

doi:10.18203/2320-6012.ijrms20233064

Authors

Ahmed Elhamalawy Primary Health Care Corporation, Doha, Qatar
Rahaf Elgonaid NHS, UK

DOI:

https://doi.org/10.18203/2320-6012.ijrms20233064

Keywords:

Africa, Tanzania, Marburg, Haemorrhagic fever, Tropical medicine

Abstract

The Marburg virus disease made headlines when Tanzania declared an outbreak on the 23^rd of March 2023. Five deaths and three further cases were identified at the time of the announcement. Symptoms of Marburg virus can include fever, headache, muscle aches, vomiting, diarrhoea, and bleeding from various parts of the body, hence the similarity to Ebola which also causes a haemorrhagic fever. There is no specific treatment for Marburg virus, but supportive care can help manage symptoms and improve outcomes. This article aims to update physicians working in primary care on the presentation of Marburg virus disease as well as the latest updates in guidelines implemented to help with its management and prevention.

Metrics

Metrics Loading ...

References

WHO. Regional Office for Africa. Tanzania confirms first-ever outbreak of Marburg Virus Disease. Available at: https://www.afro.who.int/countries/united-republic-of-tanzania/news/tanzania-confirms-first-ever-outbreak-marburg-virus-disease. Accessed on 10 June, 2023.

Centers for Disease Control and Prevention. Marburg Hemorrhagic Fever (Marburg HF). 2019. Available at: https://www.cdc.gov/vhf/marburg/index.html. Accessed on 10 June, 2023.

Languon S, Quaye O. Filovirus Disease Outbreaks: A Chronological Overview. Virol Res Treat. 2019;10:1178122X1984992.

Sohan M, Shahriar M, Bhuiyan MA, Islam MR. Recent outbreak of Marburg virus disease: Could it be a threat for global public health? Health Sci Rep. 2022;6(1).

Abir MH, Rahman T, Das A, Etu SN, Nafiz IH, Rakib A et al. Pathogenicity and virulence of Marburg virus. Virulence. 2022;13(1):609-33.

Public Health England. 2014. Viral haemorrhagic fever: ACDP algorithm and guidance on management of patients. GOV.UK. Available at: https://www.gov.uk/government/publications/viral-haemorrhagic-fever-algorithm-and-guidance-on-management-of-patients. Accessed on 10 June, 2023.

GOV.UK. Marburg virus disease: origins, reservoirs, transmission and guidelines. Available at: https://www.gov.uk/guidance/marburg-virus-disease-origins-reservoirs-transmission-and-guidelines. Accessed on 10 June, 2023.

Hamer MJ, Houser KV, Hofstetter AR, Ortega-Villa AM, Lee C, Preston A et al. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial. Lancet. 2023;401(10373):294-302.

Harris E. Marburg Vaccine Safe, Immunogenic in Phase 1 Trial. JAMA. 2023;329(9):703.

Uptodate.com. UpToDate. 2019. Available at: https://www.uptodate.com/contents/marburg-virus. Accessed on 10 June, 2023.

Marburg virus disease: A summary for clinicians. Int J Infect Dis. 23020;99:233-42.

Roy S, Iturburu A, Mukherjee D, Oduoye MO, Paul A, Akilimali A et al. Marburg virus disease outbreak amid COVID-19 pandemic: an emerging concern in Ghana, West Africa. Int J Surg. 2023;109(3):597.

Islam MR, Akash S, Rahman MM, Sharma R. Epidemiology, pathophysiology, transmission, genomic structure, treatment, and future perspectives of the novel Marburg virus outbreak. Int J Surg. 2013;109(1):36-8.

Simon JK, Kennedy SB, Mahon BE, Dubey SA, Grant-Klein RJ, Liu K et al. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials. Vaccine. 2022;40(46):6599-606.

RCGP. GP curriculum. www.rcgp.org.uk. Available at:https://www.rcgp.org.uk/mrcgp-exams/gp-curriculum. Accessed on 10 June, 2023.